This histogram enumerates side effects from a completed 2010 Phase 3 trial (NCT00319046) in the Miglustat ARM group. Side effects include: DIARRHOEA with 74%, FLATULENCE with 50%, TREMOR with 36%, HEADACHE with 21%, PARAESTHESIA with 21%.
1 Treatment Group
1 of 1
110 Total Participants · 1 Treatment Group
Primary Treatment: ATB200 · No Placebo Group · Phase 3
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.